Vitamin D binding protein macrophage-activating factor - Efranat

Drug Profile

Vitamin D binding protein macrophage-activating factor - Efranat

Alternative Names: EF-022; GcMAF; Globulin component macrophage activating factor

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Einstein Medical Center
  • Developer Efranat; Socrates Institute for Therapeutic Immunology
  • Class Antineoplastics; Carrier proteins; Lymphokines
  • Mechanism of Action Macrophage activating factor replacements; Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Recurrent respiratory papillomatosis
  • Discontinued Breast cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 11 Dec 2017 Phase I development for Solid tumours is ongoing in Israel (Efranat pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Recurrent) in Israel (IM, Injection)
  • 27 Jun 2017 Discontinued - Phase-I for Breast cancer (Metastatic disease) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top